9.3 High- and Low-Prevalence Antigens
Key Takeaways
High-prevalence antibodies (anti-k, -Kpb, -Jsb, -U, -PP1Pk, -Vel, -Ge, -Yta, -Lub) react with almost every panel cell; the autocontrol is negative if the antibody is allo.
Find antigen-negative blood through a rare-donor registry, autologous donation, or siblings — not by screening the ordinary inventory at random.
Low-prevalence antibodies (anti-Cw, -Kpa, -Jsa, -Lua, -Wra, -Dia, -V, -VS) often leave the entire screen and panel negative and declare themselves as one incompatible donor unit or unexplained HDFN.
HTLA antibodies are weak, high-titer, low-avidity, and usually insignificant; Ch/Rg are plasma-neutralizable. Do not manage them like anti-k.
The workup fork is strength + hemolysis + neutralization + autocontrol, then selected rare cells — not “order every high-prevalence typing at once.”
9.3 High- and Low-Prevalence Antigens
Quick Answer: A high-prevalence antibody (anti-k, -Kpb, -Jsb, -U, -PP1Pk, -Vel, -Ge, -Yta, -Lub) reacts with almost every panel cell. You will not find five compatible units on the shelf; you need a rare-donor registry, autologous units, or siblings. A low-prevalence antibody (anti-Cw, -Kpa, -Jsa, -Lua, -Wra, -Dia, -V, -VS) often leaves the entire screen and panel negative and shows up as one incompatible donor or unexplained HDFN. HTLA antibodies mimic high-prevalence panagglutinins but are weak, high-titer, low-avidity, and usually not clinically significant.
The June 9, 2026 outline isolates II.B.12 high-prevalence and II.B.13 low-prevalence because the bench pictures are opposites. Candidates fail both by treating every panagglutinin as HTLA and every incompatible unit as an ABO error.
What “high-prevalence” actually means
A high-prevalence (high-frequency, public) antigen is present on >90–99% of random red cells in the population you serve. The corresponding alloantibody can form only in the rare person who lacks it. Once it forms, reagent screening cells and panel cells are almost all positive. The autocontrol is negative if the antibody is allo and the patient has not been recently transfused. That combination — panreactive panel, negative auto — is the high-prevalence alarm, not a failed AHG control.
Honor these named antibodies on sight:
| Antibody | System / notes | Who lacks the antigen | Product strategy |
|---|---|---|---|
| Anti-k (Cellano) | Kell | K+k− (~0.2% European; almost always K+K+) | Rare k− units; DTT-treated cells lose the target |
| Anti-Kpb | Kell | Kp(a+b−), uncommon | Rare Kp(b−); more often European than African |
| Anti-Jsb | Kell | Js(a+b−), more often African ancestry | Rare Js(b−); do not look only in European rare files |
| Anti-U | MNS (GPB) | S−s−U−, almost exclusively African ancestry | U− or autologous; enzyme-resistant because U is close to the membrane |
| Anti-PP1Pk | P1PK/GLOB | p phenotype | p units; see Section 9.1 |
| Anti-Vel | SMIM1 | Vel− rare in all groups | Vel− rare donors; often complement-binding, may hemolyze, enzymes enhance |
| Anti-Ge (Gerbich) | GYPC | Ge− rare; some are Yus/Gerbich/Leach types | Ge− rare donors; Leach also weakens Kell |
| Anti-Yta | Cartwright (AChE) | Yt(a−) uncommon | Variable significance; DTT destroys Yt |
| Anti-Lub | Lutheran | Lu(a+b−) or Lu(a−b−) | Rare Lu(b−); mixed-field; cord cells weak |
Anti-H of Bombay, anti-P of the Pk phenotype, anti-Coa, anti-Jra, and anti-Lan belong in the same operational bucket even when a stem uses a less famous name: panreactive, auto-negative, rare antigen-negative blood.
You will not solve these by pulling ten more group O units off the shelf. The compatible donor frequency is often <1 in 1,000. The operational list is short: type the patient for the common high-prevalence antigens that fit the ethnicity and DTT/enzyme pattern, test selected rare cells (or a rare-cell panel), type siblings, arrange autologous donation if time allows, and call the American Rare Donor Program (or your regional rare file). Frozen rare units and directed sibling units are expected answers. “Issue any least-incompatible unit and stop looking” is the HTLA answer, not the anti-k answer.
Ancestry is a workup clue, not a stereotype. Js(b−) and U− concentrate in African ancestry. k− and Kp(b−) concentrate in European ancestry. Dia is a low-prevalence Diego antigen that is not rare in some South American Indigenous populations — which is why Dia sits in the low-prevalence list for U.S. panels and still causes HDFN in those families.
What “low-prevalence” actually means
A low-prevalence (low-frequency, private) antigen is present on <1–10% of random cells (often <<1%). Reagent screening cells and most panel cells lack it. The antibody screen can be entirely negative. The antibody declares itself when:
- One donor unit is incompatible at AHG and the others are fine.
- A neonate has HDFN and the maternal screen is negative.
- An eluate from a delayed HTR reacts with that donor’s cells but not with the panel.
Classic low-prevalence antibodies the outline expects you to name:
| Antibody | Antigen notes | Typical presentation |
|---|---|---|
| Anti-Cw | Rh, low-prevalence | One incompatible D+ or D− unit; can cause HDFN |
| Anti-Kpa | Kell, antithetical to Kpb | One incompatible unit; HDFN possible |
| Anti-Jsa | Kell, more often in African ancestry | One incompatible unit |
| Anti-Lua | Lutheran | Mixed-field with one donor |
| Anti-Wra | Diego/Band 3, quite immunogenic for a “low-prevalence” antigen | HDFN or one incompatible unit; many panels now include a Wr(a+) cell |
| Anti-Dia | Diego; not rare in some South American Indigenous and East Asian groups | HDFN with a “negative” U.S. panel |
| Anti-V, anti-VS | RHCE variants, more often African ancestry | One incompatible unit; RH variant context |
Workup is the reverse of the high-prevalence algorithm. You do not need a rare-donor file for the patient. You need to type the implicated donor (or father, in HDFN) for low-prevalence antigens, test the serum against that person’s cells and against a low-prevalence antigen panel, and issue units that are crossmatch-compatible. Antigen-negative inventory for Cw or Kpa is easy because almost every unit is negative. Do not delay transfusion hunting a named low-prevalence antibody if several other units are already IAT-compatible.
A low-prevalence antibody can still be clinically significant. Anti-Wra and anti-Dia have caused serious HDFN. Significance follows 37 °C / AHG behavior and history, not the word “low.”
HTLA is not a true high-prevalence emergency
High-titer, low-avidity (HTLA) antibodies — classic Ch/Rg, Knops (Kna, McCa, Sla, Yka), Cost, and many JMH — panreact at IAT and therefore look like anti-k. They are not anti-k.
| Feature | True high-prevalence (anti-k, -U, -Vel, -PP1Pk) | HTLA (Ch/Rg, Knops, many JMH) |
|---|---|---|
| Reaction strength | Often 2–4+, crisp | Weak, loose, fuzzy 1+ |
| Titer | Variable; may be low with strong avidity | High titer (often ≥64–256) with poor avidity |
| Hemolysis / complement | Vel, PP1Pk, some others hemolyze | No |
| Neutralization | No (except rare soluble antigen tricks) | Ch/Rg neutralized by plasma |
| Enzymes / DTT | Follow the system (Kell DTT-destroyed; Vel enzyme-enhanced) | Ch/Rg enzyme-destroyed; Knops weakened |
| Clinical significance | Honor — HTR / HDFN | Usually none |
| Units | Rare-donor, autologous, siblings | Ordinary IAT-compatible or least-incompatible; do not delay |
If you treat anti-Ch like anti-Vel, you will postpone a hemoglobin of 5 g/dL for a rare unit the patient does not need. If you treat anti-Vel like anti-Ch, you will issue a hemolyzing unit. The fork is strength, hemolysis, neutralization, DTT/enzyme pattern, and the patient’s ancestry — then selected cells, not a coin flip.
Workup algorithm
| Step | Finding | Next move |
|---|---|---|
| 1. Panel + autocontrol | Panreactive, auto negative | High-prevalence allo vs HTLA (not warm auto) |
| 2. Strength / titer / hemolysis | Strong or hemolytic | True high-prevalence; skip the “ignore HTLA” path |
| 3. Plasma neutralization | Reactivity gone | Ch/Rg; do not order rare units |
| 4. DTT / enzymes | DTT-destroyed | Kell, Yt, Do, JMH, LW more than Lutheran |
| 5. Patient phenotype + ancestry | k−, Js(b−), U−, Vel−, Ge−, Yt(a−), Lu(b−) | Confirm with selected rare cells |
| 6. Product | Antigen-negative rare, autologous, or sibling | Rare Donor Program; do not random-crossmatch 40 units overnight as the only plan |
| Alt: screen all negative, one unit incompatible | Auto negative, DAT negative | Low-prevalence antibody; type that donor; issue other XM-compatible units |
Recently transfused or DAT-positive panagglutinin is a different algorithm (warm auto, drug, delayed HTR). Do not force those stems into II.B.12.
Exam traps
- Calling every panagglutinin HTLA so you can ignore anti-k, anti-U, or anti-Vel.
- Calling every panagglutinin anti-k so you delay transfusion for anti-Ch.
- Expecting a U.S. three-cell screen to detect anti-Wra, anti-Cw, or anti-Dia.
- Searching the rare file for the patient who has a low-prevalence antibody (the donor is the rare cell).
- Forgetting autologous and sibling units as legitimate high-prevalence answers.
- Using African-versus-European ancestry backwards for U/Jsb versus k/Kpb.
A patient’s serum reacts 3+ at IAT with every screening cell and every panel cell. The autocontrol is negative. What is the appropriate next operational move?
Call the antibody HTLA and issue any visually least-incompatible unit without further work
Transfuse uncrossmatched group O, D-negative red cells because an unidentified antibody cannot be honored
Suspect a high-prevalence alloantibody, type the patient for plausible high-prevalence antigens, test selected rare cells, and arrange rare-donor, autologous, or sibling units
Repeat only a room-temperature screen; high-prevalence antibodies are always cold IgM
The antibody screen and a 16-cell panel are all negative. One donor unit is incompatible at IAT. The patient was not recently transfused and the DAT is negative. What is the best explanation?
The patient has anti-k and the entire panel happened to be k-negative
A low-prevalence antibody such as anti-Cw, anti-Kpa, anti-Wra, or anti-Dia reacting with one donor who carries that antigen
An HTLA antibody, because HTLA always spares screening cells and reacts with only one donor
An ABO discrepancy from Bombay anti-H, which is silent with group O screening cells
Which feature best supports an HTLA antibody rather than a clinically significant high-prevalence antibody?
Strong 4+ IAT with in-vitro hemolysis and a documented delayed hemolytic reaction
Compatibility only with k-negative cells retrieved from a rare-donor file
Mixed-field agglutination that 0.2 M DTT destroys completely, consistent with anti-K
Weak, loose IAT reactivity, titer 256 with poor avidity, and — for Ch/Rg — neutralization by plasma, without clinical hemolysis
Sections you finish are checked off in the contents.